SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis

66Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Colorectal cancer is a common disease with high mortality. Suitable biomarkers for detection of tumors at an early curable stage would significantly improve patient survival. Here, we show that the SPG20 (spastic paraplegia-20) promoter, encoding the multifunctional Spartin protein, is hypermethylated in 89% of colorectal carcinomas, 78% of adenomas and only 1% of normal mucosa samples. SPG20 methylation was also present in a pilot series of stool samples and corresponding tumors from colorectal cancer patients. SPG20 promoter hypermethylation resulted in loss of mRNA expression in various cancer types and subsequent depletion of Spartin. We further showed that Spartin downregulation in cancer cells resulted in cytokinesis arrest, which was reversed when SPG20 methylation was inhibited. The present study identifies SPG20 promoter hypermethylation as a biomarker suitable for non-invasive detection of colorectal cancer, and a possible mechanism for cytokinesis arrest in colorectal tumorigenesis. © 2011 Macmillan Publishers Limited All rights reserved.

Cite

CITATION STYLE

APA

Lind, G. E., Raiborg, C., Danielsen, S. A., Rognum, T. O., Thiis-Evensen, E., Hoff, G., … Lothe, R. A. (2011). SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene, 30(37), 3967–3978. https://doi.org/10.1038/onc.2011.109

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free